tiprankstipranks
Trending News
More News >

Cosmo Pharmaceuticals’ 2025 General Meeting Approves Dividend Increase

Story Highlights
Cosmo Pharmaceuticals’ 2025 General Meeting Approves Dividend Increase

Confident Investing Starts Here:

COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has issued an announcement.

Cosmo Pharmaceuticals N.V. announced the approval of all agenda items at its 2025 general meeting, with shareholders endorsing a 2.5% increase in dividend distribution to EUR 2.05 per share. This decision reflects the company’s commitment to creating long-term value for its stakeholders, as emphasized by the Board Chairman and CEO. The company also plans to provide further insights into its projects at the upcoming Investor Day in Zurich.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF113.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

More about COSMO Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V. is a pharmaceutical company dedicated to revolutionizing healthcare by developing innovative products that address unmet needs. Operating in Healthtech/AI, Dermatology, Gastroenterology, and contract manufacturing and development, Cosmo collaborates with global partners like Medtronic and Sun Pharma. Founded in 1997, the company is headquartered in Dublin, Ireland, with branches in the USA and Italy, employing around 330 people.

Average Trading Volume: 26,654

Current Market Cap: CHF931.1M

Find detailed analytics on COPN stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App